Data Show Amplimune® Can Reduce Likelihood of Pneumonia in Shipped Calves

NovaVive Inc.

NovaVive is a private Canadian immunobiology company founded in July, 2014. The Company acquired an advanced veterinary immunotherapeutic platform based on mycobacterium cell wall fraction (MCWF) technology with regulator-approved products for cattle, horses and dogs. These products are currently sold to veterinarians in the U.S.A., Canada, Australia and New Zealand. The Company's head office is located in Napanee, Ontario, Canada.

Sign up to stay up-to-date with NovaVive news.

Recent News

Settle® Approved for Canadian Market

NovaVive's immunotherapy for equine endometritis, Settle®, has received approval for sale in Canada from the Canadian Food Inspection Agency (CFIA). The product is expected to launch in the first quarter of this year.

learn more

MCWF Helps Improve Pregnancy per Embryo Transfer in Dairy Recipients with One Lactation

An abstract has been presented at the 2023 AETA & CETA/ACTE Joint Convention in Orlando, FL summarizing a study showing a positive effect of MCWF (Amplimune) on pregnancy per embryo transfer for dairy cows with one lactation.

learn more

Positive Data from Endometrial Cups Study with Settle® Presented at International Symposium

Data from a U.S. study using NovaVive's immunotherapy for equine endometritis, Settle®, to treat endometrial cups was presented today at the International Symposium on Equine Reproduction (ISER) in Foz do Iguaçu, Brazil.

learn more

Follow NovaVive on Social Media.